Advanced Filters
noise

Lyon Cedex 03, France Clinical Trials

A listing of Lyon Cedex 03, France clinical trials actively recruiting patients volunteers.

Found 737 clinical trials
B Benjamin DARNIS, MD

Bacterial Ecology of Pilonidal Cysts

Bacterial ecology of pilonidal cysts Single centre retrospective exploratory study of medical data contained in the medical records of patients operated on in the centre between 01/08/2020 and 30/11/2020.

18 years of age All Phase N/A

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported …

18 years of age All Phase N/A
F Florent VALOUR, Dr

Campylobacter Spp. Bone and Joint Infection: a Retrospective Cohort Study

Campylobacter bacteria, a Gram-negative bacillus commensal in the digestive tract of many animals and mainly responsible for human infections with digestive origins, has been little studied in the field of osteoarticular infections (OAI). Campylobacter spp. are, however, well described, mainly for C. fetus, and pose a dual therapeutic problem: i) …

18 - 100 years of age All Phase N/A

Hematological Anomalies in Children With Rasopathy

During childhood, patients with RASopathies (Noonan syndrome and related diseases) can harbor various hematological anomalies ranging from isolated monocytosis, myelemia, thrombocytopenia or splenomegaly to myeloproliferative disorders. These anomalies may spontaneously disappear or persist, sometimes leading to juvenile myelomonocytic leukemia. Guidelines for initial screening and subsequent hematological follow-up have recently been …

- 15 years of age All Phase N/A
C Camille Chambost

Evaluation of the Safety and Efficacy of Profhilo® Structura

Profhilo® Structura is composed of a buffered saline solution of high molecular weight (H-HA) and low molecular weight (L-HA) hyaluronic acid. The high- and low-molecular-weight HA used in the device is obtained by biofermentation and has not undergone chemical modification processes; this results in excellent tolerability of the product. In …

35 - 55 years of age All Phase N/A
M Maria PAPADOPOULOU, Dr

Music Perception in SeLECTs

Self-limited epilepsy with centrotemporal spikes (SeLECTS) is the most frequent epilepsy syndrome in children between the ages of 4 and 13 years. SeLECTS is associated in 15 to 30% of patients with specific cognitive deficits, including in particular disorders in language, visuo-spatial memory, declarative memory, and attention. SeLECTS has the …

5 - 14 years of age All Phase N/A
I Isabelle POIROT, PhD

Cohort of Children With Severe Cerebral Palsy

" Cohort CP " is a multicentre cohort study, initiated by the Hospices Civils de Lyon in September 2009. Population targeted are children with bilateral cerebral palsy, level GMFCS IV or V, aged from 2 to 10 years at inclusion. They are followed-up during 10 years, at the rhythm of …

2 - 10 years of age All Phase N/A
D Damien BODET, MD

Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

It involves collecting safety and efficacy data, under the actual conditions of use of medicines in children and adolescents, using a validated tool (Ennov EDC) and relying on the network of Interregional pediatric oncology appeal organizations (OIR) identified by INCa since 2010 and responsible for the organization of Pluridisciplinary Pediatric …

- 25 years of age All Phase N/A

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

years of age All Phase N/A
S Stephane DALLE, MD

Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma

Surgical excision is the treatment of choice for stage II, III and resectable stage IV melanoma and is curative in most cases. Given the recent success of immunotherapy for the treatment of patients with advanced metastatic melanoma, the use of immunotherapy has been evaluated in the adjuvant setting for patients …

18 years of age All Phase N/A

Simplify language using AI